The Power of Radiotherapy

The Specificity of Molecular Targeting

for Better
Patient Outcomes

Because Cancer Patients
Need a New Approach


Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic  identifies the patients with the corresponding molecular signature who are the best candidates for therapy.


Targeted Therapies
for Personalized Medicine

Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.

News & Events

Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study

Sep 22, 2017

Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…

Read More

Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling

Oct 20, 2015

Andarix’ R&D expands to include Notch Influencing Molecules   ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…

Read More

Andarix Selected to Present at Prominent Drug Development Conferences

Sep 10, 2015

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall.  Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…

Read More